论文部分内容阅读
目的探讨雌激素受体(ER)、孕激素受体(PR)、生长因子受体(HER-2)、P-糖蛋白(P-gp)和谷胱甘肽-S-转移酶(GST-π)在乳腺癌中的表达与临床意义。方法应用免疫组织化学技术,检测85例乳腺癌患者中ER、PR、HER-2和P-gp、GST-π多药耐药的表达。结果85例乳腺癌患者中ER阳性率为52%,PR阳性率为51%,HER-2阴性率为54%,P-gp检测为(-)~(+)占85%,GST-π检测为(-)~(+)占69%,与乳腺癌临床化疗有相关性。结论ER、PR、HER-2、P-gp联合表达与乳腺癌化疗密切相关,检测ER、PR、HER-2、P-gp和GST-π对乳腺癌化疗方案的制定具有重要的意义。
Objective To investigate the expression of estrogen receptor (ER), progesterone receptor (PR), growth factor receptor (HER-2), P-gp and glutathione S-transferase (GST- π) in breast cancer and its clinical significance. Methods Immunohistochemistry was used to detect the expression of ER, PR, HER-2, P-gp and GST-π in 85 breast cancer patients. Results The positive rate of ER was 52%, the positive rate of PR was 51%, the negative rate of HER-2 was 54%, the positive rate of P-gp was 85% in 85 breast cancer patients, and the positive rate of GST-π (-) ~ (+) accounted for 69%, and breast cancer is associated with clinical chemotherapy. Conclusion The combined expression of ER, PR, HER-2 and P-gp is closely related to the chemotherapy of breast cancer. Detection of ER, PR, HER-2, P-gp and GST-π is of great significance for the development of chemotherapy regimens for breast cancer.